Intravacc Awarded US$14.6 Million NIH/NIAID Contract to Develop Intranasal Gonorrhea Vaccine
Intravacc will develop a prophylactic vaccine based on its proprietary outer membrane vesicles (OMV) platform technology.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Biden to nominate U.S. surgeon general to join WHO executive board, official says
/in Health, TherapeuticsPresident Joe Biden intends to nominate Surgeon General Vivek Murthy to be the U.S. representative on the World Health Organization’s executive board, administration officials told Reuters on Tuesday.
Biden, doctors say new abortion laws have chilling impact
/in Health, TherapeuticsBiden, doctors say new abortion laws have chilling impact By Nandita Bose WASHINGTON, Oct 4 (Reuters) – U.S. President Joe Biden and top White House officials announced new guidelines and grants to protect abortion and contraception rights on Tuesday, and said women’s rights have already been curtailed since the Supreme Court overturned Roe vs. Wade […]
Omicron BA.4.6 makes up nearly 13% of COVID variants circulating in U.S. – CDC
/in Health, R&D, TherapeuticsThe U.S. Centers for Disease Control and Prevention (CDC) on Tuesday estimated that nearly 13% of the circulating coronavirus variants in the United States were of the BA.4.6 subvariant of Omicron, as of the week ended Oct. 1.
Doctors urge U.S. FDA to add miscarriage management to abortion pill label
/in FDA/Regulatory, TherapeuticsObstetricians, gynecologists, other medical professionals, and abortion rights advocates petitioned the U.S. Food and Drug Administration (FDA) on Tuesday to urge Danco Laboratories to seek approval of mifepristone, a pill used in terminating early pregnancies at home, for miscarriage management.
BMS invests in protein degradation, cell therapy platforms
/in Business, R&D, TherapeuticsBristol Myers Squibb entered two separate research collaboration and licensing deals, one with San Francisco-based SyntheX and the second with London’s Autolus Therapeutics.
Relevate Health Names New CEO
/in Marketing & AdvertisingTim Pantello will take the lead at Relevate Health, while Jeff Spanbauer assumes Chairman role.
Pfizer, Clovis make inroads against tough to treat prostate cancer
/in R&D, TherapeuticsEarly data from the Phase III TALAPRO-2 study showed Talzenna (talazoparib), Pfizer’s oral PARP inhibitor, met its primary endpoint in metastatic castration-resistant prostate cancer patients, the company announced Tuesday.
Safety concerns end KalVista angioedema trial
/in Clinical Trials, R&D, TherapeuticsLife-threatening safety concerns prompted KalVista Pharmaceuticals to shut down a mid-stage clinical trial for hereditary angioedema, the swelling of skin in response to an allergic reaction, the company announced Tuesday.
Havas Health & You appoints Paul Pfleiderer as president of Havas Life New York
/in Marketing & AdvertisingAs the rapid evolution of the health and wellness sector continues to necessitate innovative thinking and activation across the industry, Havas Health & You appointed seasoned strategic leader Paul Pfleiderer as President of Havas Life New York. Pfleiderer will work closely with Havas Life Group President Denise Henry to drive the agency’s growth and strengthen its market leadership presence through exceptional client work and culture.